Investor Relations
Our mission is to transform healthcare by redefining and restoring the functional health of the gut microbiome, which we recognize as a vital organ. Through our innovative diagnostic management tools and microbiome-based interventions, we aim to improve health span and longevity, prevent and treat chronic diseases, and shift the focus from sick care to true healthcare.
Latest Investor Update
download pdf
Pipeline
Learn More
Press Releases

Microbiota-dependent Early-life Programming of Gastrointestinal Motility
Gastrointestinal microbes modulate peristalsis and stimulate the enteric nervous system (ENS), whosedevelopment, as in the central nervous system (CNS), continues into the murine postweaning period.Given

UChicago Microbiome Startups Come Together Under New Company to Amplify Results
Two University of Chicago startups are now operating under a parent company, 32 Biosciences – with a shared goal to revolutionize health care through advances

32 Biosciences Emerges from Stealth Mode with New Approach to Gut Microbiome Medicine
32 Biosciences, pronounced “Three Squared Biosciences,” proudly announces its emergence from stealth mode, with new microbiome diagnostic management tools and microbiome-based interventions. The company intends